Overview

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of intracranially implanted Carmustine in the treatment of patients with primary malignant glioma.
Phase:
Phase 3
Details
Lead Sponsor:
Shandong Lanjin Pharmaceuticals Co.,Ltd
Treatments:
Carmustine